Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background and Purpose</h3><p>Protein tyrosine phosphatase (PTP) 1B (PTP1B) plays a critical role in the regulation of obesity, type 2 diabetes mellitus (T2DM), and other metabolic diseases. However, drug candidates exhibiting PTP1B selectivity and oral bioavailability are currently lacking. Here, the enzyme inhibitory characteristics and pharmacological benefits of BDB were investigated <i>in vitro </i> and <i>in vivo </i>. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Experimental Approach</h3><p>Surface plasmon resonance (SPR) assay was performed to validate the direct binding of BDB to PTP1B, and Lineweaver‐Burk plotting of the enzymatic reaction was used to identify the inhibition type of BDB. Both <i>in vitro </i> enzyme‐inhibition assays and SPR experiments were also conducted to study the selectivity exhibited by BDB toward four other PTP‐family proteins: TC‐PTP, SHP‐1, SHP‐2, and LAR. C2C12 myotubes were used to evaluate BDB cell permeability and effect on insulin signaling, and hypoglycemic and hypolipidemic effects of BDB were investigated in diabetic BKS db mice by using oral gavage. The beneficial effects of BDB on pancreatic islets were examined based on insulin and/or glucagon staining. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Key Results</h3><p>BDB acted as a competitive inhibitor of PTP1B and demonstrated high selectivity for PTP1B among the tested PTP‐family proteins. Moreover, BDB was cell permeable and enhanced insulin signaling in C2C12 myotubes. Lastly, oral administration of BDB produced effective antidiabetic effects in spontaneously diabetic mice and markedly improved islet architecture, which was coupled with an increase in the ratio of β‐cells to α‐cells.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion and Implications</h3><p>BDB application offers a potentially practical pharmacological approach for treating T2DM by selectively inhibiting PTP1B.</p></section>

Discovery of Novel Bromophenol 3,4-Dibromo-5-(2-bromo-3,4-dihydroxy-6-(isobutoxymethyl)benzyl)benzene-1,2-diol As Protein Tyrosine Phosphatase 1B Inhibitor and Its Anti-Diabetic Properties in C57BL/KsJ-db/db Mice.

Bromophenols As Inhibitors Of Protein Tyrosine Phosphatase 1b With Antidiabetic Properties

Discovery of Core-Structurally Novel PTP1B Inhibitors with Specific Selectivity Containing Oxindole-Fused Spirotetrahydrofurochroman by One-Pot Reaction.

Discovery of 5-(3-bromo-2-(2,3-dibromo-4,5-dimethoxybenzyl)-4,5-dimethoxybenzylidene)thiazolidine-2,4-dione as a novel potent protein tyrosine phosphatase 1B inhibitor with antidiabetic properties

Discovery of Bisindole As A Novel Scaffold for Protein Tyrosine Phosphatase 1b Inhibitors

Discovery of 2-Ethoxy-4-(methoxymethyl)benzamide Derivatives As Potent and Selective PTP1B Inhibitors.

Highly Selective Protein Tyrosine Phosphatase Inhibitor, 2,2 ',3,3 '-Tetrabromo-4,4 ',5,5 '-Tetrahydroxydiphenylmethane, Ameliorates Type 2 Diabetes Mellitus in BKS Db Mice

Synthesis and Biological Evaluation of Novel Benzyl-Substituted (S)-Phenylalanine Derivatives As Potent Dipeptidyl Peptidase 4 Inhibitors.

Synthesis and Ptp1b Inhibitory Activity of (E)-1-substitutedphenyl-3-(4-((e)-(2-(4-phenylthiazol-2-yl)hydrazono)met Hyl)Pheny1)-Prop-2-En-1-Ones

Discovery and Evaluation of the Hybrid of Bromophenol and Saccharide As Potent and Selective Protein Tyrosine Phosphatase 1B Inhibitors

Design, Synthesis of a Novel Phosphatase 1B Inhibitor and the Evaluation of Its Biology Activity and Toxicity in vitro

Identification of 1,3,4-Thiadiazolyl-Containing Thiazolidine-2,4-dione Derivatives as Novel PTP1B Inhibitors with Antidiabetic Activity

Synthesis, Biological Evaluation and 3D-QSAR Studies of Imidazolidine-2,4-dione Derivatives As Novel Protein Tyrosine Phosphatase 1B Inhibitors

Discovery and Sar of A Novel Selective and Orally Bioavailable Nonpeptide Classical Competitive Inhibitor Class of Protein-Tyrosine Phosphatase 1B

Design and Biological Evaluation of Novel Imidazolyl Flavonoids As Potent and Selective Protein Tyrosine Phosphatase Inhibitors.

Development, biological evaluation, and molecular modelling of some benzene-sulfonamide derivatives as protein tyrosine phosphatase-1B inhibitors for managing diabetes mellitus and associated metabolic disorders

Antidiabetic activity in vitro and in vivo of BDB, a selective inhibitor of protein tyrosine phosphatase 1B, from Rhodomela confervoides

Investigation of Stereoisomeric Bisarylethenesulfonic Acid Esters for Discovering Potent and Selective PTP1B Inhibitors

Synthesis of Triazole-Linked Beta-C-glycosyl Dimers As Inhibitors of PTP1B.

Synthesis and Protein Tyrosine Phosphatase 1b Inhibitory Activity of Novel Chalcone Derivatives Containing 3,4-Dihydroquinolin-2(1h)-one Moiety

Design, synthesis, biological evaluation and molecular dynamics simulation studies of imidazolidine-2,4-dione derivatives as novel PTP1B inhibitors